Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Universe PharmaceuticalsUPC -7.14%62 Debt-to-Equity is 0.17 as of Sep. 2025, which is at its 10-year median of 0.17. GuruFocus rates UPC with a GF Score™ of 62/100 and a GF Value™ of $5.18 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 812 Drug Manufacturers companies, Universe Pharmaceuticals ranks better than 62.56% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Universe Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
UPC'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.17 Max: 0.27
Current: 0.17
During the past 8 years, the highest Debt-to-Equity Ratio of Universe Pharmaceuticals was 0.27. The lowest was 0.07. And the median was 0.17.
UPC's Debt-to-Equity is ranked better than 62.56% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs UPC: 0.17
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Universe Pharmaceuticals Debt-to-Equity Related Terms
Universe Pharmaceuticals Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UPC vs CPMD, SHPH, NPHC: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universe Pharmaceuticals Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Universe Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universe Pharmaceuticals (UPC) has a Debt-to-Equity of 0.17 as of Sep. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Universe Pharmaceuticals and its competitors. This is near median its historical median of 0.17. Over the past decade, Universe Pharmaceuticals' Debt-to-Equity has ranged from 0.07 to 0.27. According to the industry distribution chart, Universe Pharmaceuticals ranks #304 out of 812 companies in the Drug Manufacturers industry, placing it in the top 37.4%.
Is Universe Pharmaceuticals' Debt-to-Equity too high?
Universe Pharmaceuticals' current Debt-to-Equity of 0.17 is near median its 10-year median of 0.17. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 0.27. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Universe Pharmaceuticals' value of 0.17 is 37% below this industry median. Based on the distribution chart, Universe Pharmaceuticals ranks #304 out of 812 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Universe Pharmaceuticals has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' Debt-to-Equity compare to CPMD and SHPH?
According to the Drug Manufacturers industry distribution chart, Universe Pharmaceuticals ranks #304 out of 812 companies for Debt-to-Equity. This puts Universe Pharmaceuticals in the upper half of its industry. The industry median Debt-to-Equity is 0.27. Universe Pharmaceuticals' value of 0.17 is 37% below this benchmark. Historically, Universe Pharmaceuticals' own Debt-to-Equity has ranged from 0.07 to 0.27 over the past decade. While the company's 10-year median is 0.17 vs. the industry median of 0.27, Universe Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Universe Pharmaceuticals's current Debt-to-Equity of 0.17 is 37% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Universe Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universe Pharmaceuticals's current Debt-to-Equity is 0.17, which is near median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.18, compared to a current price of $4.65 — trading 10.2% below its estimated fair value. The current Debt-to-Equity is 0.17, which is near median its 10-year median of 0.17 and 37% below the Drug Manufacturers industry median of 0.27. Universe Pharmaceuticals' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current Debt-to-Equity is 0.17 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Universe Pharmaceuticals (UPC) Overvalued in 2026?
Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be undervalued.
The current stock price of $4.65 is trading 10.2% below its estimated GF Value™ of $5.18.
GuruFocus considers Universe Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for UPC:
Debt-to-Equity: 0.17 (near median its 10-year median of 0.17)
GF Value™: $5.18 vs. price of $4.65 (10.2% below fair value)
Industry Position: 37% below the Drug Manufacturers median (#304 of 812)
No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
62GF Score
Get the complete analysis for UPC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPC has been successfully added to your 
